Begg, Lauren R.
Orriols, Adrienne M. http://orcid.org/0000-0002-3681-4896
Zannikou, Markella
Yeh, Chen
Vadlamani, Pranathi http://orcid.org/0000-0003-4526-9567
Kanojia, Deepak
Bolin, Rosemary
Dunne, Sara F.
Balakrishnan, Sanjeev
Camarda, Roman
Roth, Diane
Zielinski-Mozny, Nicolette A.
Yau, Christina http://orcid.org/0000-0002-1937-0859
Vassilopoulos, Athanassios
Huang, Tzu-Hsuan http://orcid.org/0000-0003-0650-582X
Kim, Kwang-Youn A. http://orcid.org/0000-0002-4168-757X
Horiuchi, Dai http://orcid.org/0000-0002-3381-0945
Funding for this research was provided by:
U.S. Department of Defense (W81XWH1810053)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA258833, P30CA060553)
Susan G. Komen (CCR16376693)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (UL1TR001422)
the Lynn Sage Breast Cancer Foundation
Article History
Received: 23 May 2023
Accepted: 29 January 2024
First Online: 20 February 2024
Competing interests
: During this study, T.H.H. was affiliated with Cancer Immunology Discovery, Pfizer, Inc., San Diego, CA, as a full-time employee and participated in this research in his capacity as an adjunct faculty member of Northwestern University’s Feinberg School of Medicine. The authors declare no competing non-financial interests, but the following competing financial interests: During this study, S.F.D. held equity interests (> US $5,000) in AbbVie and Abbott, T.H.H. held equity interests in Pfizer, and D.H. held equity interests in Merck, Eli Lilly, and AstraZeneca.